Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026GlobeNewsWire • 10/18/26
Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination PotentialSeeking Alpha • 10/07/26
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common StockGlobeNewsWire • 10/06/26
Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/09/26
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis StudyZacks Investment Research • 09/09/26
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD CombinationsGlobeNewsWire • 09/08/26
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/03/26
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid ArthritisZacks Investment Research • 08/26/26
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock TumblesBenzinga • 08/26/26
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072GlobeNewsWire • 08/25/26
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?Zacks Investment Research • 08/24/26
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?Zacks Investment Research • 08/24/26
SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?Zacks Investment Research • 08/24/26
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/04/26
Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real AssetSeeking Alpha • 06/26/26